AGC Biologics to Participate in First-Ever BIO Digital Conference

AGC Biologics | May 14, 2020

AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), will be participating in the first-ever BIO Digital event. BIO International Conference is holding its annual event virtually this year in order to safely connect industry experts amidst the COVID-19 global pandemic. The event, which takes place June 8 - 12, brings together capital, scientific and development expertise that is required to turn promising innovation into successful medicine. During the digital gathering, AGC Biologics will be holding virtual meetings with clients via the BIO One-on-One Partnering system to share information on globally aligned process development, manufacturing and seamless tech transfers. Virtual meeting times are still available to those participating. "By virtually participating in BIO Digital, AGC Biologics will continue to engage with potential partners around the globe," says AGC Biologics' CEO Patricio Massera. "Given the current economic and health safety climate, collaborations from the pharmaceutical and biotechnology sector are more important than ever." "AGC Biologics will also use this opportunity to highlight the recent expansion of its plasmid DNA (pDNA) offering," says AGC Biologics' CBO Mark Womack. "To serve the rapidly growing  demand for pDNA, AGC Biologics offers a 10-year proven track record in commercial plasmid production and a highly customizable approach for all plasmid needs." AGC Biologics will host a 20 minute virtual BIO Theater event on "Plasmid manufacturing excellence – The foundation for multiple new modalities" with speaker Mario Kraft on Wednesday, June 10th from 11:05 a.m. – 11:25 a.m. EDT.

Spotlight

Rain is a key source of water for all the species living on Earth. 71% of Earth is covered with water. When sunlight hits the water surface it causes the water evaporation which later drops in form of rain.

Spotlight

Rain is a key source of water for all the species living on Earth. 71% of Earth is covered with water. When sunlight hits the water surface it causes the water evaporation which later drops in form of rain.

Related News

INDUSTRIAL IMPACT

Novo Holdings Leads US$21M Series A Financing in BIOMILQ

Novo Holdings | October 21, 2021

BIOMILQ is developing a novel infant feeding option, derived from human mammary cells, to better meet infants' nutritional needs and with a lower carbon footprint than traditional bovine-based infant formula. Earlier this year, BIOMILQ announced it had successfully produced a milk product with many of the same macronutrients that are known to be abundantly present in breastmilk in its lab based in Research Triangle Park in North Carolina, US. In the US, it is estimated that 75%1 of women are unable to exclusively breastfeed for the six months after birth as recommended by the American Academy of Pediatrics and the World Health Organization. Breastfeeding can be difficult due to latching issues, birth complications, discomfort or pain, exhaustion, inadequate milk supply, amongst other reasons. Alternative supplements, such as bovine-based infant formula, can lack the nutritional and bioactive composition found in breast milk. BIOMILQ's technology and solutions can be transformative in the field of infant nutrition, a market with a significant need for innovation. "Our mission is to make a growing and positive impact on health, science and society. We are delighted to support BIOMILQ through its journey pioneering mammary biotechnology. Its products have the potential to disrupt the infant supplemental feeding industry. We aim to use our scientific knowledge, operational expertise and global network to further strengthen the Company's ability to improve lives. Kartik Dharmadhikari, Partner at Novo Groand BIOMILQ Board Director Michelle Egger, Chief Executive Officer and Co Founder of BIOMILQ, added: "We are very pleased to have such experienced investors in our Series A financing. Novo Holdings, as a leading international life science investor, lends significant market experience and technical knowhow to BIOMILQ's mission to nourish healthier infants, empower parents through choice, and contribute to a healthier planet. The investor syndicate was led by Novo Holdings, with participation from Breakthrough Energy Ventures, Blue Horizon, Spero Ventures, Digitalis Ventures, Green Generation Fund and Gaingels. About Novo Holdings A/S Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation's assets. Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information. About BIOMILQ BIOMILQ's mission is to close the nutritional gap between infant feeding options. In June 2021, BIOMILQ announced its capability of producing a milk product, derived from human mammary cells, that has macronutrient profiles that closely match the expected types and proportions of proteins, complex carbohydrates, fatty acids and other bioactive lipids that are known to be abundantly present in breastmilk. 1 "Breastfeeding Among U.S. Children Born 2011–2018, CDC National Immunization Survey." Centers for Disease Control

Read More

CELL AND GENE THERAPY

WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies

WuXi AppTec | March 08, 2022

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manufacture of adeno-associated virus (AAV) at Good Manufacturing Practice (GMP) grade. Developed by OXGENE in the United Kingdom, a WuXi Advanced Therapies company, TESSA™ will expedite AAV manufacturing and significantly reduce the cost for manufacturing cell and gene therapies, enabling global customers to deliver more accessible ground-breaking therapeutics to patients as quickly as possible. AAV vector is a popular tool for the delivery of gene therapies in diseases such as haemophilia and Alzheimer's. Efficient processes for manufacturing AAV on a large scale are critical to meeting increasing industry demands. TESSA™ vectors can meet the scalability challenges of AAV production, which has significant implications for expanding patient access to these novel therapeutics. The new data published in Nature Communications supports the benefits of this technology. It highlights that in the same manufacturing volume, TESSA™ vectors produced 10 times more AAV than plasmid-based manufacture, producing enough material to treat ten times the number of patients. The TESSA™ system is a game changer for the manufacture of AAV and the advancement of cell and gene therapies to benefit patients. By improving scalability, reducing process complexity and lowering the costs of gene therapy manufacture, TESSA™ will better enable our global partners to develop and deliver life-saving gene therapies faster to more patients in need." Dr. Ryan Cawood, Chief Scientific Officer of WuXi ATU. As a Contract Testing Development and Manufacturing Organization (CTDMO) with operations globally, WuXi ATU's unique business model integrates powerful testing capabilities with its advanced therapies' process development and manufacturing platforms, such as TESSA™ technology for AAV manufacturing and Lenti stable solutions for lentiviral manufacturing. This allows all assay development, biosafety, viral clearance and product release testing to be completed in-house, shortening customers' timelines for the approval of advanced therapies. About WuXi Advanced Therapies (WuXi ATU) As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies. Our services and solutions accelerate time to market and support customer programs around the world.

Read More

MEDTECH

Ochre Bio Enters into Charitable Donation Agreement with British Liver Trust

Ochre Bio | December 15, 2021

Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health. “On our path to develop next-generation RNA medicines with the potential to improve the lives of patients in need of a liver transplant, we are grateful to have access to discarded donor livers, allowing us to develop therapeutics that are safe and effective when we enter the clinical evaluation stage,” said Jack O’Meara, CEO at Ochre Bio. “As we are progressing our preclinical evaluation, we are proud to support the great work of the British Liver Trust. We highly appreciate their effort in supporting patients, caregivers, and healthcare professionals on all aspects of liver health including prevention and early detection, and we look forward to a close partnership as we execute on our unified goal.” The British Liver Trust is the UK's leading liver health charity, recognised by Her Majesty's Revenue and Customs and the Charity Commissions in England, Wales and Scotland, is working to improve liver health and supporting patients affected by liver disease or cancer. Reaching millions of people each year, the British Liver Trust raises awareness for the risk factors of liver disease, provides advice to help people improving their liver health and submits the most updated information to patients. “In the UK, one out of six patients dies while waiting for a liver transplant. Ochre Bio’s research has the potential to improve these numbers and with that the chances of successful treatment for liver disease patients. We are really excited that Ochre Bio is supporting the aims of the British Liver Trust and we delighted to have this partnership with important shared goals,” Pamela Healy OBE, Chief Executive of the British Liver Trust About Ochre Bio Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases, a top ten global killer. We uncover new biological pathways by using advances in 'deep phenotyping', and then study our medicines in human livers kept alive on machines. In doing so, Ochre Bio ensures that the medicines we bring to the clinic are highly likely to successfully improve patient lives. Situated within the heart of Oxford’s biotech innovation hub, Ochre is built on over 15 years experience in liver genomics and bringing advanced therapies to market.

Read More